| Autor: |
Sonali Narain, Charlotte Kvasnovsky, Joseph Conigliaro, Martin Lesser, Eun Ji Kim, Kevin Coppa, Jamie S Hirsch, Sara Abrahams, Jennifer Johnson, Karina W Davidson, Stuart L Cohen, Stephen C Machnicki, Alex Makhnevich, Prashant Malhotra, Lyndonna Marrast, Ramanak Mitra, Ernesto P Molmenti, M Wasif Saif, Sanjaya Satapathy, Shalin Shah |
| Jazyk: |
angličtina |
| Rok vydání: |
2021 |
| Předmět: |
|
| Zdroj: |
BMJ Open, Vol 11, Iss 2 (2021) |
| Druh dokumentu: |
article |
| ISSN: |
2044-6055 |
| DOI: |
10.1136/bmjopen-2020-042965 |
| Popis: |
Objective To describe the pattern of hydroxychloroquine use and examine the association between hydroxychloroquine use and clinical outcomes arising from changes in the US Food and Drug Administration (FDA)’s recommendation during the coronavirus disease 2019 (COVID-19) pandemic.Design A retrospective cross-sectional analysis.Setting and participants We included hospitalised adult patients at Northwell Health hospitals with confirmed COVID-19 infections between 1 March 2020 and 11 May 2020. We categorised changes in the FDA’s recommendation as pre-FDA approval (1 March 2020–27 March 2020), FDA approval (28 March 2020–23 April 2020), and FDA warning (24 April 2020–11 May 2020). The hydroxychloroquine-treated group received at least one dose within 48 hours of hospital admission.Primary outcome A composite of intubation and inpatient death.Results The percentages of patients who were treated with hydroxychloroquine were 192/2202 (8.7%) pre-FDA approval, 2902/6741 (43.0%) FDA approval, and 176/1066 (16.5%) FDA warning period (p |
| Databáze: |
Directory of Open Access Journals |
| Externí odkaz: |
|
